Scheduled Maintenance Notice

Please note that Researcher Profiles will be undergoing scheduled maintenance on Wednesday 7th Oct, from 8:00am to 9:00am. During this time, the Researcher Profiles system will be unavailable. We apologise for any inconvenience and appreciate your understanding.

Select Publications

Journal articles

Mitsuyasu RT; Merigan TC; Carr A; Zack JA; Winters MA; Workman C; Bloch M; Lalezari J; Becker S; Thornton L; Akil B; Khanlou H; Finlayson R; McFarlane R; Smith DE; Garsia R; Ma D; Law M; Murray JM; Von Kalle C; Ely JA; Patino SM; Knop AE; Wong P; Todd AV; Haughton M; Fuery C; Macpherson JL; Symonds GP; Evans LA; Pond SM; Cooper DA, 2009, 'Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34 + cells', Nature Medicine, 15, pp. 285 - 292, http://dx.doi.org/10.1038/nm.1932

Meads DM; McKenna SP; Bonney MA; Bloch MT, 2009, 'Further validation and responsiveness assessment of the herpes outbreak impact questionnaire and herpes symptom checklist', Value in Health, 12, pp. 397 - 400, http://dx.doi.org/10.1111/j.1524-4733.2008.00450.x

Martin A; Bloch MT; Amin J; Baker DL; Cooper DA; Emery S; Carr AD, 2009, 'Simplification of Antiretroviral Therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine: A Randomized, 96-Week Trial', Clinical Infectious Diseases, 49, pp. 1591 - 1601

Bodsworth N; Bloch M; McNulty A; Denham I; Doong N; Trottier S; Adena M; Bonney MA; Agnew J; Abdurahman I; Ajam A; Alexander R; Aung A; Barry S; Becker B; Belbin M; Bishop C; Bisshop F; Bourne C; Brett T; Brown K; Butler A; Carmody C; Chan D; Chuah J; Conway D; Daly C; Davies S; Davis C; Davis B; Dayan L; D'Bras L; Eisen D; Eliades C; Elisha B; Fairley C; Feiglin A; Freeman A; Furner V; Garland S; Genn W; Giannakopoulos J; Glass F; Gold J; Goswami J; Gowers A; Grech J; Hackney P; Hanson B; Hartnell K; Harvey C; Hasan M; Hawkins S; Heley S; Herbst D; Hespe C; Irlicht M; Isaacs A; Katahanas L; Kelly M; Komarowski P; Kostic G; Kozminsky M; Lagios K; Lee D; Lewis P; Liang T; Lyttle H; MacKellar-Michelmore H; MacLeod H; Marsh L; Marshall L; McCloskey J; McCurdy D; McEvoy P; McFarlane R; McKeegan P; McMurchie M; McNamee K; Medland N; Menon A; Meyerowitz C; Michaels W; Mobbs M; Montague A; Nicola N; Nurcombe C; O'Connor C; Ooi C; Ostrowskyl O; O'Sullivan M; Owen L; Papp K; Patten J; Panopoulous D; Pell C; Quan D; Quin J; Rhodes D; Rowles S, 2008, '2-Day versus 5-day famciclovir as treatment of recurrences of genital herpes: Results of the FaST study', Sexual Health, 5, pp. 219 - 225, http://dx.doi.org/10.1071/SH08013

Bodsworth N; Bloch M; McNulty A; Denham I; Doong N; Trottier S; Adena M; Bonney MA; Agnew J; Abdurahman I; Ajam A; Alexander R; Aung A; Barry S; Becker B; Belbin M; Bishop C; Bisshop F; Bourne C; Brett T; Brown K; Butler A; Carmody C; Chan D; Chuah J; Conway D; Daly C; Davies S; Davis C; Davis B; Dayan L; Donovan B; Eisen D; Eliades C; Elisha B; Fairley C; Feiglin A; Freeman A; Furner V; Garland S; Genn W; Giannakopoulos J; Glass F; Gold J; Goswami J; Gowers A; Grech J; Hackney P; Hanson B; Hartnell K; Harvey C; Hasan M; Hawkins S; Heley S; Herbst D; Hespe C; Irlicht M; Isaacs A; Katahanas L; Kelly M; Komarowski P; Kostic G; Kozminsky M; Lagios K; Lee D; Lewis P; Liang T; Lyttle H; Mackellar-Michelmore H; Macleod H; Marsh L; Marshall L; McCloskey J; McCurdy D; McEvoy P; McFarlane R; McKeegan P; McMurchie M; McNamee K; Medland N; Menon A; Meyerowitz C; Michaels W; Mobbs M; Montague A; Nicola N; Nurcombe C; O'Connor C; Ooi C; Ostrowskyl O; O'Sullivan M; Owen L; Papp K; Patten J; Panopoulous D; Pell C; Philpot R; Quan D; Quin J; Rhodes D, 2008, '2-Day versus 5-day famciclovir as treatment of recurrences of genital herpes: Results of the FaST study (Sexual Health (2008) 5, 3, (219-225))', Sexual Health, 5, pp. 379, http://dx.doi.org/10.1071/SH08013_CO

D'Arminio Monforte A; Abrams D; Pradier C; Weber R; Reiss P; Bonnet F; Kirk O; Law M; De Wit S; Friis-Møller N; Phillips AN; Sabin CA; Lundgren JD; Collins S; Loeliger E; Tressler R; Weller I; Worm SW; Sjøl A; Sawitz LA; Rickenbach M; Pezzotti P; Krum E; Gras L; Balestre E; Sundström A; Poll B; Fontas E; Torres F; Petoumenos K; Kjær J; De Wolf F; Zaheri S; Gras Athena L; Bronsveld W; Hillebrand-Haverkort ME; Prins JM; Bos JC; Eeftinck Schattenkerk JKM; Geerlings SE; Godfried MH; Lange JMA; Van Leth FC; Lowe SH; Van Der Meer JTM; Nellen FJB; Pogány K; Van Der Poll T; Ruys TA; Sankatsing ; Steingrover R; Van Twillert G; Van Der Valk M; Van Vonderen MGA; Vrouenraets SME; Van Vugt M; Wit FWMN; Van Eeden A; Ten Veen JH; Van Dam PS; Roos JC; Brinkman K; Frissen PHJ; Weigel HM; Mulder JW; Van Gorp ECM; Meenhorst PL; Mairuhu ATA; Veenstra J; Danner SA; Van Agtmael MA; Claessen FAP; Perenboom RM; Rijkeboer A; Richter C; Van Der Berg J; Van Leusen R; Vriesendorp R; Jeurissen FJF; Kauffmann RH; Koger ELW; Bravenboer B; Ten Napel CHH; Kootstra GJ; Sprenger HG; Miesen WMAJ; Doedens R; Scholvinck EH; Ten Kate RW; Van Houte DPF; Polee M; Kroon FP; Van Den B; Van Dissel JT; Schippers EF; Schreij G; Van De Geest S; Verbon A; Koopmans PP; Keuter M, 2008, 'HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies', AIDS, 22, pp. 2143 - 2153, http://dx.doi.org/10.1097/QAD.0b013e3283112b77

Sabin C; Monforte A; Friis-Moller N; Weber R; El-Sadr W; Reiss P; Kirk O; Mercie P; Law MG; De Wit S; Pradier C; Phillips A; Lundgren JD, 2008, 'Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction', Clinical Infectious Diseases, 46, pp. 1101 - 1110, http://dx.doi.org/10.1086/528862

Markowitz M; Nguyen BY; Gotuzzo E; Mendo F; Ratanasuwan W; Kovacs C; Prada G; Morales-Ramirez JO; Crumpacker CS; Isaacs RD; Gilde LR; Wan H; Miller MD; Wenning LA; Teppler H; Baker D; Bloch M; Bodsworth N; Cooper D; Workman C; Tsoukas C; Afani A; Perez J; Cortes J; Thitivichianlert S; Brown S; Galpin J; Hicks C; Kumar P; Lichtenstein K; Little S; Liporace R; Santana-Bagur J; Schwartz R; Steigbigel R; Tashima K, 2007, 'Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: Results of a 48-week controlled study', Journal of Acquired Immune Deficiency Syndromes, 46, pp. 125 - 133, http://dx.doi.org/10.1097/QAI.0b013e318157131c

Fox Z; Antunes F; Davey R; Gazzard B; Klimas N; Labriola A; Losso M; Neaton JD; Phillips A; Ruxrungtham K; Staszewski S; Weiss L; Lundgren DJ; Aguilar L; Angel EB; Aquilia S; Belloso W; Benetucci J; Bittar V; Cahn P; Casiro A; Contarelli J; Corral J; Daciuk L; David D; Ferrari I; Fridman D; Galache V; Guaragna G; Ivalo S; Laplume H; Lanusse I; Lasala MB; Lattes R; Lasovsky J; Lopardo G; Lourtau L; Lupo S; Maranzana A; Marson C; Massera L; Sanchez MDL; Somenzini C; Tocci M; Algar S; Anderson J; Baker D; Blavius K; Bloch M; Boyle M; Bradford D; Britton P; Carrall L; Carr A; Chuah J; Curry M; D'Arcy-Evans C; Dobson P; Doong N; Egan C; Ferguson W; Finlayson R; French M; Frater A; Gold J; Habel P; Haig K; Holland R; Hyland N; Hoy J; Hudson J; James R; Leung J; Lowe K; MacRae K; McMurchie M; Medland N; Miller S; Murray J; Newman R; David O; Patching J; Primrose R; Ree H; Richardson R; Rogers G; Roney J; Roth N; Sarangapany J; Shaw D; Silberberg C; Skett A; Vale R; Villella C; Walker A; Watson A; Wendt N; Wood H, 2007, 'Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ 300 cells/μL who were assigned to 7.5 MIU interleukin-2', HIV Medicine, 8, pp. 112 - 123, http://dx.doi.org/10.1111/j.1468-1293.2007.00440.x

Lowy M; Collins S; Bloch M; Gillman M; Lording D; Sutherland P; Wang H; Stecher V, 2007, 'Quality of erection questionnaire correlates: Change in erection quality with erectile function, hardness, and psychosocial measures in men treated with sildenafil for erectile dysfunction', Journal of Sexual Medicine, 4, pp. 83 - 92, http://dx.doi.org/10.1111/j.1743-6109.2006.00398.x

Emery S; Kelleher AD; Workman C; Puls R; Bloch MT; Baker D; Hoy JF; Ip S; Nalliah K; Ward L; Law MG; Cooper DA, 2007, 'Influence of IFN gamma co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy', Human Vaccines, 3, pp. 260 - 267

Collins S; Mertenskoetter T; Loeliger E; Tressler R; Weller I; Friis-Møller N; Worm SW; Sabin CA; Sjøl A; Lundgren JD; Sawitz A; Rickenbach M; Pezzotti P; Krum E; Gras L; Balestre E; Sundström A; Poll B; Fontas E; Torres F; Petoumenos K; Kjær J; Weber R; Reisswafaamel-Sadr P; Kirk O; Dabis F; Law MG; Pradier C; De Wit S; Akerlund B; Calvo G; Monforte ADA; Ledergerber B; Phillips AN; De Wolf F; Zaheri S; Bronsveld W; Hillebrand-Haverkort ME; Prins JM; Bos JC; Schattenkerk JKME; Geerlings SE; Godfried MH; Lange JMA; Van Leth FC; Lowe SH; Van Der Meer JTM; Nellen FJB; Pogány K; Van Der Poll T; Reiss P; Ruys TA; Sankatsing SU; Steingrover R; Van Twillert G; Van Der Valk M; Van Vonderen MGA; Vrouenraets SME; Van Vugt MV; Wit FWMN; Van Eeden A; Ten Veen JH; Van Dam PS; Roos JC; Brinkman K; Frissen PHJ; Weigel HM; Mulder JW; Van Gorp ECM; Meenhorst PL; Mairuhu ATA; Veenstra J; Danner SA; Van Agtmael MA; Claessen FAP; Perenboom RM; Rijkeboer A; Richter C; Van Der Berg J; Van Leusen R; Vriesendorp R; Jeurissen FJF; Kauffmann RH; Koger ELW; Bravenboer B; Ten Napel CHH; Kootstra GJ; Sprenger HG; Miesen WMAJ; Doedens R; Scholvinck EH; Ten Kate RW; Van Houte DPF; Polee M; Kroon FP; Van Den Broek PJ; Van Dissel JT; Schippers EF; Schreij G; Van De Geest S, 2006, 'Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D Study', Archives of Internal Medicine, 166, pp. 1632 - 1641, http://dx.doi.org/10.1001/archinte.166.15.1632

Gold J; Batterham MJ; Rekers H; Harms MK; Geurts TBP; Helmyr PME; Silva de Mendonça J; Carvalho LHF; Panos G; Pinchera A; Aiuti F; Lee C; Horban A; Gatell J; Phanuphak P; Prasithsirikul W; Gazzard B; Bloch M; Danner SA, 2006, 'Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wasting', HIV Medicine, 7, pp. 146 - 155, http://dx.doi.org/10.1111/j.1468-1293.2006.00358.x

Pett SL; Wand H; Law MG; Arduino R; Lopez JC; Knysz B; Pereira LC; Pollack S; Reiss P; Tambussi G; Abrams DI; Cooper DA; Darbyshire JH; Duncan WR; Emery S; Clifford Lane H; Lehrman S; Lundgren JD; Neaton JD; Aguilar L; Angel EB; Aquilia S; Belloso W; Benetucci J; Bittar V; Cahn P; Casiro A; Contarelli J; Corral J; Daciuk L; David D; Ines F; Fridman D; Galache V; Guaragna G; Ivalo S; Laplume H; Lasala MB; Lattes R; Lasovsky J; Lopardo G; Losso M; Lourtau L; Lupo S; Maranzana A; Marson C; Massera L; del Lujan Sanchez M; Somenzini C; Tocci M; Algar S; Anderson J; Austin D; Baker D; Blavius K; Bloch M; Boyle M; Bradford D; Carrall L; Carr A; Chuah J; Curry M; D'Arcy-Evans C; Dobson P; Doong N; Ferguson W; Finlayson R; French M; Gold J; Habel P; Hoy J; Hudson J; James R; Jeganathan S; Leung J; Lowe K; MacRae K; Mallal S; McMurchie M; Medland N; Mijch A; Miller S; Murray J; Orth D; Patching J; Primrose R; Quan D; Rawlinson M; Ree H; Richardson R; Rogers G; Roney J; Roth N; Shaw D; Soo TM; Sowden D; Street A; Street A; Vale R, 2006, 'Evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial (ESPRIT): Geographical and gender differences in the baseline characteristics of participants', HIV Clinical Trials, 7, pp. 70 - 85, http://dx.doi.org/10.1310/4733-ACQF-F3P4-2QAC

Bloch MT; Smith DE; Quan D; Kaldor JM; Zaunders J; Petoumenos K; Irvine K; Law MG; Grey PA; Finlayson R; Mcfarlane R; Kelleher AD; Carr AD; Cooper DA, 2006, 'The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: Final results from a randomized clinical trial (Pulse)', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 42, pp. 192 - 202

Kinloch-De Loes S; Hoen B; Smith DE; Autran B; Lampe FC; Phillips AN; Goh LE; Andersson J; Tsoukas C; Sonnerborg A; Tambussi G; Girard PM; Bloch M; Battegay M; Carter N; El Habib R; Theofan G; Cooper DA; Perrin L, 2005, 'Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection', Journal of Infectious Diseases, 192, pp. 607 - 617, http://dx.doi.org/10.1086/432002

Chee CC; Mortier E; Dupont C; Bloch M; Simonpoli AM; Rouveix E, 2005, 'Medical and social differences between French and migrant patients consulting for the first time for HIV infection', AIDS Care Psychological and Socio Medical Aspects of AIDS HIV, 17, pp. 516 - 520, http://dx.doi.org/10.1080/09540120412331291760

Winston A; Bloch MT; Carr AD; Amin J; Mallon PW; Ray J; Marriott D; Cooper DA; Emery S, 2005, 'Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy', Journal of Antimicrobial Chemotherapy, 56, pp. 380 - 387

Ray J; Marriott D; Bloch MT; McLachlan AJ, 2005, 'Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic', British Journal of Clinical Pharmacology, 60, pp. 291 - 299

Van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJP; Schechter M; Murphy RL; Horban A; Hall DB; Lange JMA; Reiss P, 2004, 'Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1', Plos Medicine, 1, pp. 064 - 074, http://dx.doi.org/10.1371/journal.pmed.0010019

Martin A; Smith D; Carr A; Hoy J; Chuah J; Mallal S; Law M; Clements M; Cooper DA; Macrae K; James R; Mijch A; McCormack C; Baker D; McLeod H; Kidd J; McFarlane R; Vale R; Roth N; Wood H; Finlayson R; Bodsworth N; Wheatley D; Austin D; Bloch M; Frater A; Doong N; Hudson J; Anderson J; Patching J; Leung J; Lee W; Sharkey T; Wand H, 2004, 'Progression of lipodystrophy (LD) with continued thymidine analogue usage: Long-term follow-up from a randomized clinical trial (the PIILR study)', HIV Clinical Trials, 5, pp. 192 - 200, http://dx.doi.org/10.1310/0GU7-6X27-MMHE-5ALE

Mortier E; Toure S; Seyler C; Bloch M; Anglaret X, 2003, 'Urinary pH in HIV-infected adults in Ivory Coast and in France [3]', AIDS, 17, pp. 2003 - 2005, http://dx.doi.org/10.1097/00002030-200309050-00028

Levy Y; Durier C; Krzysiek R; Rabian C; Capitant C; Lascaux AS; Michon C; Oksenhendler E; Weiss L; Gastaut JA; Goujard C; Rouzioux C; Maral J; Delfraissy JF; Emilie D; Aboulker JP; Gougeon ML; Metro A; Viard JP; Bouchenafa K; Jung C; Mortier E; Bloch M; Chandemerle C; Gérard L; Martinie M; Kazatchkine M; Laureillard D; Dinh TT; Dalmas AM; Peretti D; Rannou MT; Bazin C; Verdon R; Six M; Goubin P; Vittecoq D; Escaut L; Malet M; Maignan A; Bouvet E; Prevot MH; Fournier I; Gaudebout C; Yéni P; Belarbi L; Mandet C; Zucman D; Majerholc C; Boue F; Estocq GA; Delavalle AM; Pasquali JL; Lalanne H; Bouchet-Delbos L; Chambenoit C; Carmagnat MV; Grangeot-Keros L; Ameisen JC; Estaquier J; Monnier D; Ferchal F; Girard PM; Laplanche A; Bazin B; Foubert V; Izard S; Martins J; Netzer E, 2003, 'Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: A randomized controlled trial', AIDS, 17, pp. 343 - 351, http://dx.doi.org/10.1097/00002030-200302140-00008

Emery S; Abrams D; Cooper DA; Darbyshire JH; Lane HC; Lundgren JD; Neaton JD, 2002, 'The evaluation of subcutaneous proleukin® (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials', Control Clin Trials, 23, pp. 198 - 220

Kaufmann GR; Bloch MT; Finlayson RJ; Zaunders J; Smith DE; Cooper DA, 2002, 'The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy', AIDS, 16, pp. 359 - 367

Bloch M, 2001, 'Current tren HIV therapy', Current Therapeutics, 42, pp. 8 - 12

Bodsworth NJ; Bloch M; Bower M; Donnell D; Yocum R; The International Panretin® Gel KS Study Group , 2001, 'Phase III Vehicle-Controlled, Multi-Centered Study of Topical Alitretinoin Gel 0.1% in Cutaneous AIDS-Related Kaposi’s Sarcoma', American Journal of Clinical Dermatology, 2, pp. 77 - 87, http://dx.doi.org/10.2165/00128071-200102020-00004

Stewart GJ; Ashton LJ; Biti RA; Ffrench RA; Bennetts BH; Newcombe NR; Benson EM; Carr A; Cooper DA; Kaldor JM; Anderson B; Allworth A; Ashton L; Baker D; Batty G; Beveridge A; Bloch M; Bodsworth N; Carr A; Clare K; Cooper D; Cummins E; Cunningham P; Couldwell D; Deacon N; Doong N; Finlayson R; Ffrench R; Furner V; Huffam S; Kaldor J; Kidd J; Kelly M; Lloyd A; McFarlane R; McLean K; McNulty A; McPhee D; Michelmore H; McMurchic M; Mutimer K; Peterson J; Price R; Quan D; Quin J; Ree H; Robertson M; Roggensack M; Schroeder K; Smith D; Spencer D; Stewart G; Sullivan J; Ziegler J, 1997, 'Increased frequency of CCR-5 Delta 32 heterozygotes among long-term non-progressors with HIV-1 infection', AIDS, 11, pp. 1833 - 1838, http://dx.doi.org/10.1097/00002030-199715000-00007

Bloch MW; Smith DA; Nelson DL, 1989, 'Heart rate, activity, duration, and affect in added-purpose versus single-purpose jumping activities.', American Journal of Occupational Therapy Official Publication of the American Occupational Therapy Association, 43, pp. 25 - 30, http://dx.doi.org/10.5014/ajot.43.1.25


Back to profile page